

The listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1-8. (Cancelled)

9. (Currently Amended) A method according to claim 11 8, wherein the estrogen sulfamate is estrone sulfamate, estradiol sulfamate, estriol sulfamate, N-acylsulfamate of estrone, estradiol or estriol having an acyl chain of up to 7 C atoms or mixtures thereof.

10. (Cancelled)

11. (Currently Amended) A method of achieving hormone replacement therapy in a woman comprising intermittently orally administering an estrogen sulfamate at a dosage of 0.5-5.0 mg on each day when administered in intervals of 5-10 days according to claim 8, wherein the intermittent oral administration is carried out at an interval of 5 to 10 days between administrations.

12. (Cancelled)

13. (Currently Amended) A method of achieving hormone replacement therapy in a woman comprising intermittently orally administering an estrogen sulfamate at a dosage of 2.0-20 mg on each day when administered in intervals of 20-40 days according to claim 8, wherein the intermittent oral administration is carried out at an interval of 20 to 40 days between administrations.

14. (Currently Amended) A method according to claim 11 8, further comprising the administration of a gestagen.

15. (Currently Amended) A method according to claim 14, wherein the at least one gestagen is levonorgestrel, desogestrel, norethisterone, medroxyprogesterone acetate, megestrol, cyproterone acetate, chlormadinone acetate, dienogest, drospirenone or a mixture thereof.

16. (Previously Presented) A method according to claim 14, wherein the at least one gestagen is continuously administered.

17. (Previously Amended) A method according to claim 16, wherein the continuous administration is in the form of an implant, in the form of an intrauterine release system or in the form of a combination thereof.